Glaukos (GKOS) Competitors

Glaukos (NYSE:GKOS) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Do insiders & institutionals have more ownership in GKOS or ZBH?

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 6.4% of Glaukos shares are owned by insiders. Comparatively, 1.0% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has more volatility and risk, GKOS or ZBH?

Glaukos has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Do analysts recommend GKOS or ZBH?

Glaukos currently has a consensus price target of $145.92, suggesting a potential downside of 3.29%. Zimmer Biomet has a consensus price target of $123.33, suggesting a potential upside of 15.14%. Given Zimmer Biomet's higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Zimmer Biomet	2 Sell rating(s)	11 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.25

Does the MarketBeat Community believe in GKOS or ZBH?

Zimmer Biomet received 455 more outperform votes than Glaukos when rated by MarketBeat users. Likewise, 67.16% of users gave Zimmer Biomet an outperform vote while only 64.77% of users gave Glaukos an outperform vote.

Company	Underperform	Outperform
Glaukos	Outperform Votes 445 64.77%	Underperform Votes 242 35.23%
Zimmer Biomet	Outperform Votes 900 67.16%	Underperform Votes 440 32.84%

Does the media favor GKOS or ZBH?

In the previous week, Zimmer Biomet had 2 more articles in the media than Glaukos. MarketBeat recorded 15 mentions for Zimmer Biomet and 13 mentions for Glaukos. Glaukos' average media sentiment score of 0.96 beat Zimmer Biomet's score of 0.77 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings & valuation, GKOS or ZBH?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$360.35M	23.09	-$134.66M	-$3.02	-49.96
Zimmer Biomet	$7.60B	2.81	$1.02B	$5.26	20.37

Is GKOS or ZBH more profitable?

Zimmer Biomet has a net margin of 14.27% compared to Glaukos' net margin of -42.43%. Zimmer Biomet's return on equity of 12.95% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-42.43%	-18.99%	-11.47%
Zimmer Biomet	14.27%	12.95%	7.55%

Summary

Zimmer Biomet beats Glaukos on 11 of the 19 factors compared between the two stocks.